These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8993367)

  • 1. Fab' fragments of a mAb to a member of family 2 of trans-sialidases of Trypanosoma cruzi block trypanosome invasion of host cells and neutralize infection by passive immunization.
    Villalta F; Smith CM; Burns JM; Chaudhuri G; Lima MF
    Ann N Y Acad Sci; 1996 Oct; 797():242-5. PubMed ID: 8993367
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of antibody and protective immune responses against Trypanosoma cruzi infection elicited by immunization with a parasite antigen delivered as naked DNA or recombinant protein.
    Pereira-Chioccola VL; Costa F; Ribeirão M; Soares IS; Arena F; Schenkman S; Rodrigues MM
    Parasite Immunol; 1999 Feb; 21(2):103-10. PubMed ID: 10101720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Passive transfer of a monoclonal antibody specific for a sialic acid-dependent epitope on the surface of Trypanosoma cruzi trypomastigotes reduces infection in mice.
    Franchin G; Pereira-Chioccola VL; Schenkman S; Rodrigues MM
    Infect Immun; 1997 Jul; 65(7):2548-54. PubMed ID: 9199418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibodies inhibiting Trypanosoma cruzi trans-sialidase activity in sera from human infections.
    Leguizamón MS; Campetella O; Russomando G; Almiron M; Guillen I; Ganzález Cappa SM; Frasch AC
    J Infect Dis; 1994 Dec; 170(6):1570-4. PubMed ID: 7995998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune system pathogenesis is prevented by the neutralization of the systemic trans-sialidase from Trypanosoma cruzi during severe infections.
    Risso MG; Pitcovsky TA; Caccuri RL; Campetella O; Leguizamón MS
    Parasitology; 2007 Apr; 134(Pt 4):503-10. PubMed ID: 17166319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of a trans-sialidase-ISCOMATRIX subunit vaccine candidate to protect against experimental Chagas disease.
    Bontempi IA; Vicco MH; Cabrera G; Villar SR; González FB; Roggero EA; Ameloot P; Callewaert N; Pérez AR; Marcipar IS
    Vaccine; 2015 Mar; 33(10):1274-83. PubMed ID: 25625671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A ligand that Trypanosoma cruzi uses to bind to mammalian cells to initiate infection.
    Villalta F; Smith CM; Ruiz-Ruano A; Lima MF
    FEBS Lett; 2001 Sep; 505(3):383-8. PubMed ID: 11576533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma cruzi infection in mice.
    Costa F; Franchin G; Pereira-Chioccola VL; Ribeirão M; Schenkman S; Rodrigues MM
    Vaccine; 1998 May; 16(8):768-74. PubMed ID: 9627933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Applicability of Neutralizing Antibodies to Trypanosoma cruzi Trans-sialidase.
    Leguizamón MS
    Methods Mol Biol; 2019; 1955():239-246. PubMed ID: 30868532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Antigens in Trypanosoma cruzi].
    Búa JE; Bontempi EJ; Ruiz AM; Segura EL
    Rev Argent Microbiol; 1990; 22(1):37-55. PubMed ID: 2125741
    [No Abstract]   [Full Text] [Related]  

  • 11. Trans-sialidase recombinant protein mixed with CpG motif-containing oligodeoxynucleotide induces protective mucosal and systemic trypanosoma cruzi immunity involving CD8+ CTL and B cell-mediated cross-priming.
    Hoft DF; Eickhoff CS; Giddings OK; Vasconcelos JR; Rodrigues MM
    J Immunol; 2007 Nov; 179(10):6889-900. PubMed ID: 17982080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trypanosoma cruzi trans-sialidase: enhancement of virulence in a murine model of Chagas' disease.
    Chuenkova M; Pereira ME
    J Exp Med; 1995 May; 181(5):1693-703. PubMed ID: 7722448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo infection by Trypanosoma cruzi: the conserved FLY domain of the gp85/trans-sialidase family potentiates host infection.
    Tonelli RR; Torrecilhas AC; Jacysyn JF; Juliano MA; Colli W; Alves MJ
    Parasitology; 2011 Apr; 138(4):481-92. PubMed ID: 21040619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel protective antigens expressed by Trypanosoma cruzi amastigotes provide immunity to mice highly susceptible to Chagas' disease.
    Silveira EL; Claser C; Haolla FA; Zanella LG; Rodrigues MM
    Clin Vaccine Immunol; 2008 Aug; 15(8):1292-300. PubMed ID: 18579696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with an engineered mutant trans-sialidase highly protects mice from experimental Trypanosoma cruzi infection: a vaccine candidate.
    Fontanella GH; De Vusser K; Laroy W; Daurelio L; Nocito AL; Revelli S; Contreras R
    Vaccine; 2008 May; 26(19):2322-34. PubMed ID: 18403070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The repetitive domain of Trypanosoma cruzi trans-sialidase enhances the immune response against the catalytic domain.
    Buscaglia CA; Campetella O; Leguizamón MS; Frasch AC
    J Infect Dis; 1998 Feb; 177(2):431-6. PubMed ID: 9466532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Trypanosoma cruzi trans-sialidase family members as targets of protective CD8+ TC1 responses.
    Wizel B; Nunes M; Tarleton RL
    J Immunol; 1997 Dec; 159(12):6120-30. PubMed ID: 9550413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies against Trypanosoma cruzi neuraminidase reveal enzyme polymorphism, recognize a subset of trypomastigotes, and enhance infection in vitro.
    Prioli RP; Mejia JS; Pereira ME
    J Immunol; 1990 Jun; 144(11):4384-91. PubMed ID: 2111345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody to Trypanosoma cruzi neuraminidase enhances infection in vitro and identifies a subpopulation of trypomastigotes.
    Cavallesco R; Pereira ME
    J Immunol; 1988 Jan; 140(2):617-25. PubMed ID: 3121750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal vaccinations with the trans-sialidase antigen plus CpG Adjuvant induce mucosal immunity protective against conjunctival Trypanosoma cruzi challenges.
    Giddings OK; Eickhoff CS; Sullivan NL; Hoft DF
    Infect Immun; 2010 Mar; 78(3):1333-8. PubMed ID: 20048046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.